Have a personal or library account? Click to login
Pharmacological targeting of PD-L1/PD-1 signaling in gynecological cancers Cover

Pharmacological targeting of PD-L1/PD-1 signaling in gynecological cancers

Postępy Higieny i Medycyny Doświadczalnej
Volume 79 (2025): Issue 1 (January 2025)
By: Ammad Ahmad Farooqi,  Gürkan Özbey,  Sundas Fayyaz and  Cristina Donfrancesco  
Open Access
|Mar 2025

Figures & Tables

Figure 1.

PD-L1/PD-1 signaling causes exhaustion of natural killer cells and T cells
PD-L1/PD-1 signaling causes exhaustion of natural killer cells and T cells

Figure 2.

c-Myc and STAT3 transcriptionally upregulate PD-L1. FOXO3 inhibits the expression of PD-L1
c-Myc and STAT3 transcriptionally upregulate PD-L1. FOXO3 inhibits the expression of PD-L1

Figure 3.

(A-B) GATA1 transcriptionally activates LINC01503. LINC01503 interferes with miR-766-5p-mediated targeting of PD-L1. (C) PVT1 activates STAT3 signaling and consequent upregulation of PD-L1
(A-B) GATA1 transcriptionally activates LINC01503. LINC01503 interferes with miR-766-5p-mediated targeting of PD-L1. (C) PVT1 activates STAT3 signaling and consequent upregulation of PD-L1
DOI: https://doi.org/10.2478/ahem-2025-0004 | Journal eISSN: 1732-2693
Journal RSS Feed
Language: English
Page range: 25 - 34
Submitted on: Jun 28, 2024
|
Accepted on: Jan 27, 2025
|
Published on: Mar 5, 2025
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
cancer,
metastasis,
PD-L1/PD1 signaling,
apoptosis,
metastatic dissemination,
signaling cascades
Related subjects:
Life sciences,
Molecular biology,
Microbiology and virology,
Medicine,
Basic medical science,
Immunology

© 2025 Ammad Ahmad Farooqi, Gürkan Özbey, Sundas Fayyaz, Cristina Donfrancesco, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 79 (2025): Issue 1 (January 2025)Next article